82 results about "Bacillus smegmatis" patented technology

The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP and when the first recombination attachment site is attP, the second recombination attachment site is attB. The invention also describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors and methods of the present invention are also useful in gene therapy applications.

A natural preservative composition obtained from plant materials provides antimicrobial activity for various compositions such as a food composition. The antimicrobial agent is effective in inhibiting the growth of gram-positive Staphylococcus aureus, gram-negative Escherichia coli, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa, acid-fast bacterium Mycobacterium smegmatis, the yeast Candida albicans. The antimicrobial agent has a MIC of 3.0 μl / ml capable of inhibiting these organisms. The antimicrobial agent includes mixtures of Origanum vulgare L., Thymus vulgaris L., Cinnamomum zeylanicum Nees, Rosmarinum officinalis L., Lavandula officinalis L., Hydrastis canadensis L. and olive leaf extract. The antimicrobial agent is an effective natural alternative to commonly used synthetic ingredients for product preservation.

Disclosed is an O-phosphoserine sulfhydrylase (OPSS) mutant which has a Mycobacterium smegmatis-derived amino acid sequence corresponding to that of SEQ ID NO: 1 which is devoid of three to seven C-terminal amino acid residues. Also, a nucleic acid molecule encoding the OPSS mutant, an expression vector carrying the nucleic acid molecule, and a transformant transformed with the expression vector are disclosed. In addition, a method is provided for producing cysteine in which O-phospho-L-serine (OPS) is reacted with a sulfide in the presence of the OPSS mutant. The OPSS mutant has improved enzymatic activity and can be applied to the environmentally friendly production of L-cysteine through a simple enzymatic conversion reaction.

Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are Mycobacterium smegmatis expressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.

The invention discloses a new application of naphthoquine phosphate and application of the naphthoquine phosphate in preparation of an antibacterial drug. The naphthoquine phosphate has the action of inhibiting hormodendrum compactum, hormodendrum dermatitidis, fonsecaea pedrosoi, microsporum gypseum, stellate thyton mentagrophytes, trichophyton verrucosum, microsporum canis, colon bacillus, staphylococcus albus, ataphylococcus aureus, mycobacterium tuberculosis (M.tuberculosis), mycobacterium smegmatis and staphylococcus epidermidis, has remarkable therapeutic effect on infection of the ataphylococcus aureus, the mycobacterium tuberculosis and trichophyton and is a very potential broad-spectrum antibacterial compound. With the antifungal action and the actions of a common pathogen of the naphthoquine phosphate, a novel broad-spectrum antibiotic drug with the action of resisting the common pathogen and the antifungal action is provided to people.

The invention discloses a recombinant plasmid. The recombinant plasmid contains a gp120 gene of the monkey immunodeficiency virus and at least one cell wall carrier protein gene of Mycobacterium tuberculosis. The invention also discloses recombinant mycobacterium smegmatis which can stably express the gp120 gene of the monkey immunodeficiency virus and at least one cell wall carrier protein gene of Mycobacterium tuberculosis. The invention also discloses an AIDS vaccine and a preparation method thereof. The AIDS vaccine contains the recombinant mycobacterium smegmatis, is easy to culture, grows fast and saves time, labor, material resources and financial resources. The vaccine comprising three strains of the recombinant mycobacterium smegmatis ZWY2 exhibiting the SIV gp120 antigen proteinon the surface can stably exhibit the SIV gp120 antigen protein on the surface of the mycobacterium smegmatis ZWY2 and has the immunological effect in C57 mice far superior to that of intracellular expression of the antigen protein gp120 and that of the already published AIDS vaccine exhibiting gp120 on the surface based on adenovirus vector construction.

The invention discloses a production method of glycine. The invention provides a method for constructing an engineering strain capable of producing glycine, and the method comprises the following steps of: expressing glyoxylic acid ammoniation enzyme from mycobacterium smegmatis, paucisalibacillus globuius, mycobacterium tuberculosis, bacillus aquimaris, halomonas boliviensis, aeromonas veronii or labrenzia aggregata by recipient bacteria, thus obtaining a strain named as an engineering bacterium 1; the engineering bacterium 1 is an engineering strain capable of producing glycine. The invention opens up the precedent of synthesizing glycine by using a biological method.